The Importance of Real-World Data in CAR T-Cell Therapy

In terms of CAR T-cells, I think the real-world data are really, very helpful. There was an excellent study initiated by Doris Hunson. She presented data from patients receiving Ida Cell at the last international myeloma workshop in Ashlast. And they found that 77% which is the majority of their patients would not be study eligible for the CARMA trial. Most common reasons were comorbidities, cytopenias, Prabicium A-target therapy.

Play episode from 10:13

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app